InvestSMART

Neurizon Therapeutics Limited (ASX:NUZ)

ALERT: Price-sensitive ASX Announcement for NUZ
Current share price for NUZ : $0.059 -0.086 (-59.31%)+
Announcement
Release
6 Oct 2025 8:55AM
Price at Release
$0.145
Full Release
download
Summary
Neurizon Therapeutics Limited announced that the U.S. FDA has lifted the clinical hold on NUZ-001, an investigational therapy for ALS. This clearance allows the drug to enter the HEALEY ALS Platform Trial in Q4 CY2025. The IND for NUZ-001 is supported by extensive preclinical safety data and manufacturing quality information from a licensing agreement with Elanco. This milestone sets a regulatory foundation to accelerate the development of NUZ-001, potentially slowing ALS progression and opening pathways for future partnering opportunities. Neurizon is collaborating with key opinion leaders and advocacy groups to advance this treatment.
Key Points
  • FDA lifts clinical hold on NUZ-001.
  • NUZ-001 to enter HEALEY ALS Platform Trial in Q4 CY2025.
  • Supported by preclinical data and Elanco agreement.
  • Potential to slow ALS progression.
  • Regulatory foundation for accelerated development.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.